DaVita HealthCare Partners Inc logo

DaVita HealthCare Partners Inc(DVA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
SELL
SELL for 1 day
PROFIT SINCE LAST BUY
-10.4% ▼
LAST CLOSE
$174.56
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for DVA

11/13/2026: DVA (2-star) is a SELL. SELL for 1 day. Simulated Profits (-10.40%). Updated daily EoD!

DaVita HealthCare Partners Inc is a specialized healthcare services company operating a leading network of outpatient dialysis clinics across the United States. The company's main strengths lie in its deep clinical expertise, dense facility footprint, and reliable generation of free cash flow driven by essential patient treatments. Its primary growth story centers on expanding home dialysis modalities and value-based integrated care partnerships. Key risks include heavy reliance on government reimbursement rates, potential regulatory compliance scrutiny, and sensitivity to commercial payer mix. The stock suits value-oriented investors seeking stable, cash-generative healthcare exposure, with ongoing monitoring required around labor costs and federal healthcare policy shifts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitRevenue growth is characteristically slow and steady rather than high-octane.
Momentum investorStrong fit while signal remains positiveThe stock can experience sustained upward trends driven by share buybacks and earnings beats when market sentiment is favorable.
Value investorStrong fitThe company trades at reasonable valuation multiples backed by consistent cash generation and earnings quality.
Dividend investorWeak fitDaVita does not pay a regular cash dividend, favoring share repurchases instead.
Low-risk investorMixed fitWhile demand for dialysis is defensive, regulatory and reimbursement uncertainties introduce structural risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock experiences moderate price swings influenced by broader market conditions and healthcare policy news.
Valuation riskLowTrading multiples typically reflect stable, predictable cash flows without extreme speculative premiums.
Competition risk (duopoly and specialized providers)MediumDaVita operates in a concentrated market alongside major peers like Fresenius, limiting aggressive market share grabs.
Business qualityStrongThe company maintains high operating margins and strong economic moats in specialized outpatient care.
Dividend incomeLow / noneIncome-focused investors receive no direct cash return via dividends.
Execution riskMediumOperational success depends heavily on managing clinical labor costs and maintaining stringent regulatory compliance.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 10.98B USD
Price to earnings Ratio 13.21
1Y Target Price 222.29
Price to earnings Ratio 13.21
1Y Target Price 222.29
Volume (30-day avg) 777.1K shares
Beta 0.86
52 Weeks Range 101.00 - 247.49
Updated Date 11/15/2026
52 Weeks Range 101.00 - 247.49
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 13.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 4%
Avg. Invested days 47
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
DVA receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
DVA has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 9.6%) is partially offset by negative earnings growth (-20.2%), moderate revenue growth (+6.5%), soft profitability (net margin 5.5%).

Financial Health Rating

★★★★★
DVA's financial health is supported by strong cash strength, including free-cash-flow generation of $1.3B (9.6% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is DVA's strongest growth driver at +6.5% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-20.2%, negative) and free-cash-flow growth (-10.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 51.3% and approximately 53.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 47.91% supports management-shareholder alignment.

Top 5 Institutional Investors

Berkshire Hathaway Inc 45.91%
BlackRock Inc 3.91%
Vanguard Capital Management, LLC 3.34%
Morgan Stanley - Brokerage Accounts 2.55%
Vanguard Portfolio Management, LLC 2.19%

Unit Economics (Per $1K Revenue)

★★★★★
DVA generates approximately $270 of gross profit, $147 of operating income, and $96 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.76%

Quantitative Style Profile

★★★★★
DVA has a high-quality, large-cap, liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
U.S. Dialysis and Patient ServicesOutpatient hemodialysis treatments, peritoneal dialysis services, and administered pharmaceuticals in domestic clinics.This is the core engine of the company, generating recurring revenue from regular patient visits.
Ancillary Services and Strategic InitiativesIntegrated kidney care arrangements, clinical laboratory testing, and international dialysis operations.Provides secondary revenue streams and positions the company for value-based care reimbursement models.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 3.78
Actual 3.82

Profitability

Profit Margin 6.49%
Operating Margin (TTM) 15.17%

Management Effectiveness

Return on Assets (TTM) 7.59%
Return on Equity (TTM) 96.79%

Valuation

Trailing PE 13.21
Forward PE 9.48
Enterprise Value 23.81B
Price to Sales(TTM) 0.78
Enterprise Value 23.81B
Price to Sales(TTM) 0.78
Enterprise Value to Revenue 1.68
Enterprise Value to EBITDA 8.48
Shares Outstanding 62.90M
Shares Floating 33.44M
Shares Outstanding 62.90M
Shares Floating 33.44M
Percent Insiders 47.91
Percent Institutions 51.3

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.